These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28070890)

  • 1. The Role of Conventional and Right-Sided ECG Screening for Subcutaneous ICD in a Tetralogy of Fallot Population.
    Alonso P; Osca J; Cano O; Pimenta P; Andrés A; Yagüe J; Millet J; Rueda J; Sancho-Tello MJ
    Pacing Clin Electrophysiol; 2017 Feb; 40(2):145-153. PubMed ID: 28070890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conventional and right-sided screening for subcutaneous ICD in a population with congenital heart disease at high risk of sudden cardiac death.
    Alonso P; Osca J; Rueda J; Cano O; Pimenta P; Andres A; Sancho MJ; Martinez L
    Ann Noninvasive Electrocardiol; 2017 Nov; 22(6):. PubMed ID: 28508439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity and specificity of the subcutaneous implantable cardioverter defibrillator pre-implant screening tool.
    Zeb M; Curzen N; Allavatam V; Wilson D; Yue A; Roberts P; Morgan J
    Int J Cardiol; 2015 Sep; 195():205-9. PubMed ID: 26048376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator.
    Groh CA; Sharma S; Pelchovitz DJ; Bhave PD; Rhyner J; Verma N; Arora R; Chicos AB; Kim SS; Lin AC; Passman RS; Knight BP
    Heart Rhythm; 2014 Aug; 11(8):1361-6. PubMed ID: 24755323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eligibility for subcutaneous implantable cardioverter-defibrillator in congenital heart disease.
    Wang L; Javadekar N; Rajagopalan A; Rogovoy NM; Haq KT; Broberg CS; Tereshchenko LG
    Heart Rhythm; 2020 May; 17(5 Pt B):860-869. PubMed ID: 32354451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation?
    Randles DA; Hawkins NM; Shaw M; Patwala AY; Pettit SJ; Wright DJ
    Europace; 2014 Jul; 16(7):1015-21. PubMed ID: 24351884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous implantable cardioverter defibrillator eligibility according to a novel automated screening tool and agreement with the standard manual electrocardiographic morphology tool.
    Francia P; Ziacchi M; De Filippo P; Viani S; D'Onofrio A; Russo V; Adduci C; Biffi M; Ferrari P; Bianchi V; Ammendola E; Palano F; Frisoni J; Valsecchi S; Lovecchio M; Bongiorni MG
    J Interv Card Electrophysiol; 2018 Jun; 52(1):61-67. PubMed ID: 29502193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eligibility for subcutaneous implantable cardioverter-defibrillator in adults with congenital heart disease.
    Zormpas C; Silber-Peest AS; Eiringhaus J; Hillmann HAK; Hohmann S; Müller-Leisse J; Westhoff-Bleck M; Veltmann C; Duncker D
    ESC Heart Fail; 2021 Apr; 8(2):1502-1508. PubMed ID: 33538124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of electrocardiographic screening failure for the subcutaneous implantable cardioverter-defibrillator in children: A prospective multicenter study.
    Campbell M; Moore JP; Sreeram N; von Alvensleben JC; Shah A; Batra A; Law I; Sanatani S; Thomas V; Nik-Ahd F; Williams S; Nosavan N; Maldonado J; Hart A; Nguyen T; Balaji S
    Heart Rhythm; 2018 May; 15(5):703-707. PubMed ID: 29309839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eligibility for subcutaneous implantable cardioverter defibrillators in the adult congenital heart disease population.
    Garside H; Leyva F; Hudsmith L; Marshall H; de Bono J
    Pacing Clin Electrophysiol; 2019 Jan; 42(1):65-70. PubMed ID: 30394548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.
    Maurizi N; Olivotto I; Olde Nordkamp LR; Baldini K; Fumagalli C; Brouwer TF; Knops RE; Cecchi F
    Heart Rhythm; 2016 Feb; 13(2):457-63. PubMed ID: 26362577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of subcutaneous implantable cardioverter-defibrillator based on template ECG screening and ineligible surface ECG predicting factors in patients with hypertrophic cardiomyopathy in China.
    Guo L; Zhang M; Hu M; Wang B; Wang J; Zuo L; Yang W; Liu B; Liu L
    Heart Vessels; 2019 May; 34(5):851-859. PubMed ID: 30465278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional and alternative preimplantation ECG screening for subcutaneous ICD in high risk hypertrophic cardiomyopathy patients.
    Kaczmarek K; Kałowski M; Krzysztof Wranicz J; Ptaszyńsk P; Cygankiewicz I
    J Electrocardiol; 2020; 58():68-73. PubMed ID: 31770668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dialytic interval and the timing of electrocardiographic screening for subcutaneous cardioverter-defibrillator placement in chronic hemodialysis patients.
    You C; Sharma S; Bavishi A; Groh CA; Alia Y; Saour B; Passman R
    J Interv Card Electrophysiol; 2018 Jul; 52(2):179-184. PubMed ID: 29525912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Screening Electrocardiogram for the Subcutaneous Defibrillator in Adults with Congenital Heart Disease.
    Thomas VC; Peterson M; McDaniel M; Restrepo H; Rothman A; Jain A
    Pediatr Cardiol; 2017 Aug; 38(6):1162-1168. PubMed ID: 28534239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential eligibility of congenital heart disease patients for subcutaneous implantable cardioverter-defibrillator based on surface electrocardiogram mapping.
    Zeb M; Curzen N; Veldtman G; Yue A; Roberts P; Wilson D; Morgan J
    Europace; 2015 Jul; 17(7):1059-67. PubMed ID: 25678600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of routine right parasternal electrocardiographic screening in assessing eligibility for subcutaneous implantable cardioverter-defibrillator.
    Arias MA; Pachón M; Sánchez-Iglesias I; Loughlin G; Martín-Sierra C; Puchol A; Sabatel F; Rodríguez-Padial L
    J Cardiovasc Electrophysiol; 2020 Jan; 31(1):103-111. PubMed ID: 31724763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison of the novel automated screening tool (AST) versus the manual screening tool (MST) in patients with already implanted subcutaneous ICD.
    Bögeholz N; Pauls P; Güner F; Bode N; Fischer A; Dechering D; Frommeyer G; Köbe J; Wasmer K; Eckardt L; Reinke F
    Int J Cardiol; 2018 Aug; 265():90-96. PubMed ID: 29885706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening.
    Olde Nordkamp LRA; Warnaars JLF; Kooiman KM; de Groot JR; Rosenmöller BRAM; Wilde AAM; Knops RE
    J Cardiovasc Electrophysiol; 2014 May; 25(5):494-499. PubMed ID: 24320684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.